Last reviewed · How we verify
escitalopram, sertraline, duloxetine or venlafaxine XR
escitalopram, sertraline, duloxetine or venlafaxine XR is a Small molecule drug developed by Alar Pharmaceuticals Inc.. It is currently in Phase 1 development.
At a glance
| Generic name | escitalopram, sertraline, duloxetine or venlafaxine XR |
|---|---|
| Sponsor | Alar Pharmaceuticals Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Nausea
- Insomnia
- Dry Mouth
- Fatigue
- Diarrhoea
- Constipation
- Dizziness
- Upper Respiratory Tract Infection
- Hyperhidrosis
- Nasopharyngitis
- Akathisia
Key clinical trials
- Multiple Ascending Dose Phase 1 Study of ALA-3000 (PHASE1)
- A Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression (PHASE3)
- A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression (PHASE3)
- A Study of Intranasal Esketamine Plus an Oral Antidepressant for Relapse Prevention in Adult Participants With Treatment-resistant Depression (PHASE3)
- A Study to Evaluate the Efficacy, Safety, and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression (PHASE3)
- A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression (PHASE3)
- A Study to Evaluate the Efficacy, Safety, and Tolerability of Intranasal Esketamine Plus an Oral Antidepressant in Elderly Participants With Treatment-resistant Depression (PHASE3)
- A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- escitalopram, sertraline, duloxetine or venlafaxine XR CI brief — competitive landscape report
- escitalopram, sertraline, duloxetine or venlafaxine XR updates RSS · CI watch RSS
- Alar Pharmaceuticals Inc. portfolio CI
Frequently asked questions about escitalopram, sertraline, duloxetine or venlafaxine XR
What is escitalopram, sertraline, duloxetine or venlafaxine XR?
escitalopram, sertraline, duloxetine or venlafaxine XR is a Small molecule drug developed by Alar Pharmaceuticals Inc..
Who makes escitalopram, sertraline, duloxetine or venlafaxine XR?
escitalopram, sertraline, duloxetine or venlafaxine XR is developed by Alar Pharmaceuticals Inc. (see full Alar Pharmaceuticals Inc. pipeline at /company/alar-pharmaceuticals-inc).
What development phase is escitalopram, sertraline, duloxetine or venlafaxine XR in?
escitalopram, sertraline, duloxetine or venlafaxine XR is in Phase 1.
What are the side effects of escitalopram, sertraline, duloxetine or venlafaxine XR?
Common side effects of escitalopram, sertraline, duloxetine or venlafaxine XR include Headache, Nausea, Insomnia, Dry Mouth, Fatigue, Diarrhoea.